Early diagnosis improves the prognosis of young people with rheumatic diseases

The DRFZ is running various long-term registers to monitor young patients with rheumatic diseases. Since 2007, the JuMBO biologics register has been providing important information on the long-term efficacy and tolerability of anti-rheumatic drugs in patients with juvenile idiopathic arthritis (JIA). The data on more than 1,500 young patients show that early intensive treatment improves the prognosis in adulthood. The more consistently JIA is treated from the outset, the more often patients achieve drug-free remission in young adulthood and the less often they have co-morbidities.